Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAGIR: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
NCT05110001Phase 3Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of rose bengal in Acanthamoeba keratitis (AK), fungal keratitis (FK) and corneal ulcer (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Best Spectacle-Corrected Visual Acuity at 6 months. Started Aug 2022; status: completed.
02
Drugs
rose bengal
03
Conditions
Acanthamoeba keratitis (AK)fungal keratitis (FK)corneal ulcer
Beyond the preview
Go deeper on NCT05110001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110001.